{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"The MTD of panobinostat was defined as the dose at which the continual reassessment method (CRM) estimated that 25% of patients were expected to experience DLTs. For Stratum 2, non-progressed DIPG or H3K27M+ thalamic diffuse malignant glioma (DMG) patients who completed conventional radiation treatment were eligible. All patients enrolled on this stratum had DIPG tumors and were treated with the \"3 times/week, every other week\" schedule (1 course = 28 days).","groups":[{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients who were treated with the \"3 times/week, every other week\" schedule.","id":"OG000","title":"Stratum 2"}],"paramType":"NUMBER","populationDescription":"Patients who were enrolled on stratum 2 and were evaluable for dose finding assessment were used to determine the MTD for stratum 2. Of 34 patients enrolled on stratum 2, 5 patients were not evaluable due to: receiving less than required dose of study drug (2), disease progression before active treatment (1), withdrawal/refusal prior to protocol therapy (1), and insufficient labs to monitor for dose-limiting toxicities (1). The remaining 29 patients were used to determine the MTD for stratum 2.","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Maximum Tolerated Dose (MTD) of Panobinostat in Stratum 2","type":"PRIMARY","unitOfMeasure":"mg/m^2/day"}